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Transparency review of pharmaceutical 
administration and policies
Hannes Wahlroos
Professor, Director General
National Agency for Medicines
Editorial
The second government of Finnish Prime Minister Matti
Vanhanen is currently extensively reorganising the gov-
ernment administration and its structures. Central ad-
ministration is being reorganised by transferring execu-
tive responsibilities from the ministries down to lower
levels of administration. The responsibilities of the min-
istries and the national boards will be clearly distin-
guished, and the responsibilities of the national boards
will be reassessed. The government first successfully
demonstrated its capacity for reorganisation by creating
the new Ministry of Employment and the Economy
(MEE) in record time. The government is involved in de-
velopment and reorganisation projects in almost all ad-
ministrative areas.
Far-reaching development projects are also underway
in the Ministry of Social Affairs and Health, from the
Ministry itself right through to the various agencies and
institutions. The Ministry’s new organisational structure
came into effect at the beginning of May. In addition to
these projects, work is also being carried out to improve
transparency in the fields of pharmaceutical administra-
tion and policy.
No administration or bureaucracy is an end in itself.
Thus from time to time it is entirely appropriate to re-
view and restructure an administration, and adjust the
way in which policies are managed and coordinated.
This has not happened in the pharmaceutical sector since
the beginning of the 1990’s, when the structures govern-
ing the present administration and activities were created.
Since that time, Finland has reached the historic land-
mark of EU membership, and pharmaceutical and med-
ical devices regulation has been Europeanised.
Good decisions need to be preceded by good reviews
and proposals. On this occasion, the Ministry of Social
Affairs and Health has decided to turn to Professor Jussi
Huttunen, a highly experienced expert in review issues,
for assistance in the development of pharmaceutical ad-
ministration. By invitation at the beginning of February,
Professor Huttunen was given a review task on how best
to redirect resources and improve the activities and
working methods of NAM and the Centre for Pharma-
cotherapy Development, and, with regard to pharmaceu-
tical administration, of the National Research and Devel-
opment Centre for Welfare and Health (STAKES) and
the National Public Health Institute. It was also request-
ed that a review be carried out of the involvement of the
Social Insurance Institution in the assessment of the ther-
apeutic value of drugs. Professor Huttunen submitted an
interim report on this at the end of March, which was
followed by a consultation round. In its statement, NAM
emphasised the importance of consolidating resources,
expert advice and administration1.
The third item under review was the responsibilities
borne by the Ministry of Social Affairs and Health and
by the Drug Pricing Board with regard to pharmaceutical
issues. The deadline for this part of the review (final re-
port) was at the end of May. In addition to his involve-
ment in the issues under review described above, Profes-
sor Huttunen, in his capacity as a reviewer of the admin-
istration of pharmaceutical policies, was also invited to
become a member of the lead group for the project de-
veloping the structure and activities of the Ministry. One
of the aims of this project, which will end in October, is
to improve strategic activities in this area of administra-
tion, and to develop the NAM guidelines.
Not only Finnish bodies have been involved in evalu-
ating and reviewing Finland’s pharmaceutical policies.
Even during the previous government, the Ministry of
Social Affairs and Health invited Professor Elias Mossia-
los from the London School of Economics to review the
problems faced and options available with regard to
pharmaceutical policy in Finland. This report was pub-
lished in March this year2. Key observations from the re-
port include deficiencies with regard to the coordination
of pharmaceutical policies, and inadequate expertise.
At last, adequate efforts have been made to review
the situation. Concrete guidelines and principles are now
needed for the future development of pharmaceutical ad-
ministration and policy. NAM hopes that the solutions
will take into account the challenges anticipated in the
2010’s, and will be based on effective leading principles
in pharmaceutical administration.
1 http://www.laakelaitos.fi/instancedata/prime_product_ 
julkaisu/laakelaitos/embeds/Ajankohtaista_Lausunnot_
LL_Lausunto_valiraportista_180408.pdf
2 Mossialos E & Srivastava D. Pharmaceutical Policies in 
Finland. Challenges and opportunities. http://www.euro. 
who.int/ Document/E91239.pdf
Systemic lupus erythematosus
(SLE) is a connective tissue dis-
ease with widely varying symp-
toms. They may vary from very
mild skin and joint symptoms to
severe organ damage such as kid-
ney and central nervous system
symptoms. The periodic character
of the stages of activity are also
typical of the disease. SLE is an
example of a connective tissue
disease with a number of associ-
ated immunological abnormali-
ties, e.g. the production of anti-
bodies and immune complexes
and tissue damage resulting from
immunological disorders (1). The
diagnosis of SLE is based on the
updated classification criteria of
the American College of Rheuma-
tology (ACR) of the year 1997
(Table 1). A minimum of four out
of the 11 criteria are necessary
for the diagnosis of SLE.
Hydroxychloroquine
Hydroxychloroquine (HCQ) has
been the primary drug in the
treatment of SLE for a long time,
used especially in the treatment
of the milder symptoms of the
disease, such as skin and joint
symptoms, treatment of serositis
and mild haematological changes
(1). The mechanisms of action of
the drug are not fully known, but
it has been proven to decrease the
production of inflammation 
inducing cytokines, e.g. inter-
leukin-1, interleukin-6 and tu-
mour necrosis factor-alpha (2, 3).
It reduces platelet aggregation
and adhesion (4). It also has a
favourable effect on the levels of
lipids: HCQ reduces the levels of
triglycerides and LDL (5, 6), it al-
so has a hypoglycaemic effect (6). 
Several follow-up studies have
been carried out examining the
benefits of treatment with HCQ
in SLE patients. Its long-term use
has protected SLE patients
against the activity stages of the
disease (7, 8) and reduced the
risk for thrombo-embolytic
events in SLE patients (9). Long-
term use also prevents permanent
organ damage caused by SLE in
the patients and improves the
prognosis for survival (9, 10). In
a Spanish follow-up study (11)
SLE patients on anti-malarial
medication were, during a 10-
year follow-up period, found to
have fewer malignancies in com-
parison with the control group.
Methotrexate and 
azathioprine
Methotrexate is often also used
in the treatment of mild and
moderate SLE symptoms. There
are several non-randomised stud-
ies on the use of methotrexate in
SLE with proven response espe-
cially in skin and joint symptoms
(12). Methotrexate therapy can
also be used in the treatment of
other SLE symptoms, those of
myositis and serositis, for exam-
ple (13, 14). In two randomised
studies (15, 16) methotrexate
therapy reduced the general dis-
ease activity in SLE patients in
comparison with placebo. The
daily dose of prednisone was also
smaller in the group receiving the
actual drug in comparison with
the placebo group.
Azathioprine is probably the
most common immunosuppres-
sive drug used as a corticosteroid-
sparing therapy in the treatment
of SLE. Azathioprine is generally
not used at the acute stage of the
disease, it is instead a primary
drug for many SLE patients who
have recurrent activation stages
and a need for increased doses of
corticosteroids.
Riitta Heikkilä
MD
Helsinki University Central Hospital
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Table 1. Classification criteria for SLE
(ACR 1997)
1.   Butterfly rash
2.   Lupus discoides
3.   Photosensitivity
4.   Ulcers of the oral mucosa
5.   Arthritis
6.   Serositis (e.g. pleuritis, pericarditis)
7.   Kidney damage (recurring proteinuria 
> 0.5 g/day or cell casts)
8.   Neurological symptoms (e.g. epileptic   
seizure, psychosis)
9.   Haematological abnormality 
(haemolytic anaemia, leukopenia or 
lymphopenia at least twice, 
thrombocytopenia)
10. Immunological abnormality 
(DNA-antibodies, Sm-antibodies or 
phospholipid antibodies)
11.  Positive antinuclear antibody
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is
an immunosuppressive drug in-
creasingly used in the treatment
of SLE (17). It inhibits the prolif-
eration of lymphocytes B and T
and decreases the production of
antibodies. It has no immunolog-
ical effect on kidney cells. Exper-
imentally it reduces the prolifera-
tion of mesangial cells. In animal
models, MMF inhibits the
glomerular, tubular and intersti-
tial cell proliferation. It exerts a
minor effect only on other tissues
with a high degree of cell prolif-
eration (skin, bone marrow, neu-
trophils). Consequently, the drug
generally has fewer side effects
compared with cyclophos-
phamide, for example. The most
common side effects of MMF are
intestinal symptoms: nausea,
vomiting, diarrhoea. Its use is
not associated with significant
ovarian toxicity as with the use
of cyclophosphamide therapy
(17). MMF therapy has been
used in a number of manifesta-
tions of SLE, such as skin symp-
toms, haematological changes
and the treatment of nephritis, in
particular. Response has also
been achieved in such SLE pa-
tients who have not previously
benefitted from other immuno-
suppressive therapies (18, 19).
Lupus nephritis 
Lupus nephritis is one of the
most important symptoms influ-
encing the prognosis for SLE pa-
tients (1). The WHO classifica-
tion divides kidney changes into
six categories (Table 2). The in-
duction treatment established for
severe proliferative lupus nephri-
tis is intravascular corticosteroid
and cyclophosphamide (CYC)
pulse therapy (CYC 0.5–1g/m2
and a monthly steroid for 6
months followed by pulse thera-
pies at 3-month intervals for a to-
tal period of two years). Pro-
longed treatment has resulted in
improved response and fewer re-
currences compared with 6
months of treatment. The treat-
ment has improved the prognosis
for patients with nephritis (20,
21, 22). Nevertheless, cyclophos-
phamide therapy is associated
with significant risks of side ef-
fects, such as leucopenia-induced
problems of infection, gonado-
toxicity and possible risk of ma-
lignancy (23, 24). Consequently
and understandably, therapies
and management programs with
fewer adverse events are being in-
vestigated. In the Euro-Lupus
Nephritis Trial (25) comparisons
were made between a high-dose
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Table 3. Management scheme for severe lupus nephritis (28)
Induction treatment 
*  Intravenous methyl prednisolone 1 g/3 days or oral prednisone 1 mg/kg, slow reduction of dose +
Alternatively 
*  CYC or *  MMF 2–3 g/day for 6 months.
*  Normal: 0.5–1 g/m2 intravenously/month x 6 or
*  Euro-Lupus: 500 mg intravenously at 2-week intervals x 6
If no response, replaced by CYC <–> MMF
or rituximab 
Maintenance treatment
*  Low-dose prednisone +
*  MMF 1-2 g/day        or *  Azathioprine 1-2 mg/kg/day
Supportive treatment 
*   ACE inhibitor / AT II antagonist 
*   Protection of the skeletal system 
*   Primary and secondary prevention of cardiovascular diseases
Table 2. Classification of lupus nephritis 
(WHO)
I. Normal
II. Mesangial glomerulonephritis (GN)
III. Focal proliferative GN 
IV. Diffuse proliferative  GN
V. Membranous GN
VI. Sclerosing GN
cyclophosphamide therapy
(monthly intravenous doses of
0.5–1g/m2 for six months fol-
lowed by two additional infu-
sions) and lighter dosage (an in-
travenous dose of 500 mg at 2-
week intervals administered six
times). The maintenance therapy
for both groups consisted of oral
azathioprine. The average follow-
up period was 41 months. Varia-
tions in remission (54% vs. 71%)
or recurrence (29% vs. 27%) of
kidney disease were not seen be-
tween the treatment groups. Pa-
tients who had received lighter
treatment experienced fewer ad-
verse events. The tendency in 
cyclophosphamide therapy is in
fact to introduce shorter manage-
ment periods and smaller cumula-
tive drug doses.
The use of MMF in the induc-
tion treatment of severe lupus
nephritis is compared with CYC
therapy in four randomised stud-
ies. The number of patients treat-
ed totalled 268, with lupus
nephritis of category III–IV mani-
fested in the majority of them. In
the meta-analysis (26) of these
four studies, patients of the MMF
group achieved remission in their
kidney disease more frequently in
comparison with others; the rela-
tive risk of failure of the induc-
tion treatment in the MMF man-
agement group was 0.70. Similar
results in favour of the MMF
group were also seen in the other
endpoint events: the relative risk
of end-stage kidney disease or
mortality was 0.44 in comparison
with the CYC management
group. The studies have been car-
ried out in patients who suffered
from severe lupus nephritis with
fairly intact kidney function. In
the maintenance treatment of lu-
pus nephritis, CYC therapy has
been compared with azathioprine
and MMF therapy (27). Overall,
azathioprine and MMF achieved
superior responses and were asso-
ciated with fewer side effects in
comparison with maintenance
treatment with CYC. Table 3
shows the present management
algorithm in the treatment of se-
vere proliferative lupus nephritis
(28).
Rituximab
Rituximab is a chimeric mono-
clonal antibody for B cell surface
receptor CD20. Surface receptors
CD20 are found in all immature
and mature B cells, except plasma
cells. Rituximab therapy results
in a transient deficiency in B cells
(29). The official therapeutic indi-
cation of rituximab is the treat-
ment of severe rheumatoid arthri-
tis (at a dose of 1 g intravenously
every other week, administered
twice) and lymphoma (375
mg/m2 weekly, administered four
times). Encouraged by the good
results of treatment in rheuma-
toid arthritis, rituximab has also
been tried in the treatment of SLE
and other autoimmune diseases.
There are a number of reports
(30) on the use of rituximab in
SLE patients, but not a single
controlled study has been carried
out. Treatment responses in se-
vere forms of the disease have
been described where no reaction
to other treatments has been
achieved. Good results have been
described in the treatment, for
example, of lupus nephritis, CNS
symptoms and haematological
changes and in the management
of general disease activity. Ritux-
imab does not, however, have an
official therapeutic indication for
the treatment of SLE. In the liter-
ature two SLE patients have been
described who developed severe
progressive multifocal leucoen-
cephalopathy (PML) following
rituximab therapy. PML is a rare,
severe and often fatal demyelinat-
ing disease which occurs in se-
verely immunosuppressed pa-
tients. There is an underlying
polyomavirus JC infection, which
may become activated in im-
munosuppressed patients. Nearly
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Table 4. Occurrence of neuropsychiatric 
symptoms of SLE (32)
Central nervous system
1.  Aseptic meningitis 
2.  Cerebrovascular disease 
3.  Demyelinating syndrome
4.  Headache (e.g. migraine, 
idiopathic intracranial 
hypertension)
5.  Movement disturbances 
(chorea)
6.  Myelopathy 
7.  Epileptic seizures 
8.  Acute confusion 
9.  Anxiety disorder 
10. Cognitive dysfunction 
11. Mood disorder 
12. Psychosis 
Peripheral nervous system 
1.  Acute inflammatory demyeli -
nating polyradiculopathy 
(Guillain-Barré’s syndrome)
2.  Autonomic nervous system
disorder 
3.  Mononeuropathy 
4.  Myasthenia gravis
5.  Cranial neuropathy 
6.  Plexopathy
7.  Polynephropathy
2/3 of the cases of PML de-
scribed in association with
rheumatoid arthritis have oc-
curred in SLE patients. Many of
these patients have not been on
high-dose immunosuppressive
medication, and it is consequent-
ly suspected that SLE by itself
could cause exposure to progres-
sive multifocal leucoencephalopa-
thy (31).
Central nervous system lupus
About 50% of SLE patients ex-
hibit neuropsychiatric symptoms
at some stage of the disease. The
neuropsychiatric symptoms of
SLE manifested were classified in
1999, the classification includes a
total of 19 syndromes (32) (Table
4). A fairly recent review (33) in-
cluded retrospective monitoring
of 41 patients with CNS lupus
from 1990 to 2002. The dura-
tion of SLE which the patients
had suffered was on average 5.75
years at the time of onset of the
CNS symptoms. The most com-
mon symptoms included
headache (54%), epileptic
seizures (42%), visual distur-
bances (32%), tiredness (27%),
hemiparesis (24%), memory dis-
order (24%) and confusion
(24%). The CNS symptoms in
10 patients (24%) were the ini-
tial symptoms of the disease and
the patients were at a later stage
diagnosed with SLE. The majori-
ty of the patients (36/41) were on
corticosteroid therapy. In some
of the patients it was combined
with immunosuppressive therapy.
Some of the patients received
other supportive treatment, such
as antithrombotic medication or
warfarin, anti-epileptic or an-
tiparkinsonian medication. At the
end of the follow-up period five
patients (12%) were symptom-
free, 17 patients (42 %) had mild
difficulties, 12 (32%) had moder-
ate difficulties and two (5%) had
severe difficulties in coping. Five
patients (12%) died.
Prognosis
Mortality among SLE patients is
3–5-fold in comparison with the
rest of the population. The prog-
nosis for patients has neverthe-
less significantly improved during
recent decades. In the 1950’s the
5-year survival rate prognosis for
SLE patients was about 50%.
The 10-year survival rate prog-
nosis for the patients at present is
about 80%. The most important
causes of fatal outcome include
the degree of severity of the dis-
ease and especially the severity of
the kidney disease, infections,
cardiovascular diseases and ma-
lignant tumours (1).
A prospective European fol-
low-up study examined the caus-
es of death of SLE patients in the
years from 2000 to 2004 (34).
Data of about 2,500 SLE patients
from 12 centres were compiled
over a period of five years. Dur-
ing the follow-up period 91 pa-
tients had died. The mean dura-
tion of the disease at the time of
death was 10.2 years (0.1–40
years). In 1/3 of the patients the
SLE was in remission at the time
of death. In the rest of the pa-
tients, the severity of the disease
together with organ damage con-
tributed to the fatal outcome. In
those patients who had suffered
from the disease for less than five
years the SLE at an active stage
contributed to the fatal outcome
more often than it did in the
long-term sick. The most com-
mon causes of death included in-
fections and cardiovascular dis-
eases. The most common infec-
tions included pneumonia and
unspecified sepsis. The most com-
mon fatal cardiovascular diseases
included myocardial infarction,
heart failure, sudden death and
ischaemic cerebral events. End-
stage kidney failure was a con-
tributing factor to the fatal out-
come in 17.8% and cancer in 
8% of the patients (lymphoma
3%, leukaemia 2%, solid tumour
3%).
The risk of cardiovascular dis-
eases is increased in SLE patients.
For example, the frequency of
hypertension, diabetes and hyper-
cholesterolaemia is higher than
usual in SLE patients. In addition
to the conventional risk factors,
SLE is considered to be an inde-
pendent risk factor for athero-
sclerosis. Long-term inflammato-
ry diseases cause endothelial and
vascular damage with subsequent
exposure to the development of
atherosclerosis (35). In order to
improve the prognosis for SLE
patients their management should
be aimed at active treatment of
the primary disease. The manage-
ment should also focus on the
conventional risk factors of ath-
erosclerosis and associated treat-
ment (36).
See literature on page 7.
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ACE inhibitors, angiotensin receptor blockers,
renin inhibitors or a combination of these in the
treatment of hypertension?
The key importance of the renin-
angiotensin system in the patho-
physiology of cardiovascular dis-
eases was only detected in the
1970’s (1). Nowadays, among
the renin- angiotensin system in-
hibitors, the angiotensin convert-
ing enzyme (ACE) inhibitors are
widely used in the treatment of
hypertension and heart failure (2,
3). Angiotensin receptor blockers
(ARBs), which inhibit the an-
giotensin II binding to type 1 an-
giotensin II (AT1) specific recep-
tors in blood vessels and other
tissues, reduce the prevalence of
cardiovascular diseases, including
mortality (4). The most recent
group of drugs in use are renin
inhibitors (1, 5–7), which specifi-
cally inhibit the cleavage of an-
giotensinogen to angiotensin I.
(Pro)renin receptor blockers are
also under development.
Renin-angiotensin system
Plasma renin activity is a limiting
factor in the rate of formation of
the most important biologically
active compound of the renin-an-
giotensin system, angiotensin II
(Fig.). In the kidneys, in the walls
of the afferent arterioli, there are
specific smooth muscle cells (jux-
taglomerular cells), which secrete
renin into the blood when the
sodium balance is negative or the
blood pressure is reduced. Renin
breaks down angiotensinogen in-
to angiotensin I in the blood (2,
3).
Angiotensin I (angiotensin 1-
10) is transformed into a potent
vasoconstrictor, angiotensin II
(angiotensin 1–8) by the an-
giotensin converting enzyme
(Fig.). Angiotensin II is further
cleaved into angiotensin III (an-
giotensin 2–8) by aminopeptidas-
es. Angiotensin III is biologically
active and its stimulating effect
on aldosterone secretion is al-
most as potent as that of an-
giotensin II, but its hypertensive
effect is only one quarter of that
of angiotensin II.
Effects of angiotensin II on
the target cells are mediated via
specific angiotensin receptors, of
which there are two main sub-
types, AT1 and AT2 receptors (2,
3). The angiotensin receptors in
most tissues are mainly AT1  re-
ceptors, which mediate all the
known hypertensive effects of an-
giotensin II. The physiological
importance of AT2 receptors still
remains unclear, but their num-
ber is increased in hypertrophic
cardiac tissue and in hyperplastic
vascular intima. Activation of
AT2 receptors may actually be
associated with the inhibition of
hypertrophy, fibrosis and prolif-
eration, and with vasodilatation
(2, 3) (Fig.). 
ACE inhibitors
ACE inhibitors reduce the trans-
formation of angiotensin I to an-
giotensin II both systemically
and locally (Fig.). Since ACE in-
hibitors reduce the formation of
angiotensin II, renin and angio-
tensin I blood concentrations are
increased due to the interruption
of the normal feedback suppres-
sion of renin secretion. ACE in-
hibitors inhibit the degradation
of vasodilating bradykinin and
increase the formation of vasodi-
lating prostaglandins and nitric
oxide; they may promote blood
pressure lowering effect and inhi-
bition of left ventricular hyper-
trophy. Due to the effect of ACE
inhibitors aldosterone secretion
is reduced, because angiotensin II
is an important regulator of al-
dosterone production. During
ACE inhibitor therapy the for-
mation of angiotensin 1–7 is in-
creased, which may also partly
explain the pharmacological ef-
fects of ACE inhibitors.
The most common (5–20%)
adverse reaction of ACE in-
hibitors is a cough. It occurs
more often in women compared
Heikki Ruskoaho
Professor
Institute of Biomedicine 
Department of Pharmacology and Toxicology
University of Oulu
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with men, it usually starts 1 week
–6 months after the start of drug
therapy and the reaction is not
dose-dependent. The cough may
be caused by the accumulation of
bradykinin, substance P, neu-
rokinin A or prostaglandin in the
bronchi (2, 3). Severe, but rare
(0.1–0.2%), adverse reactions
caused by ACE inhibitors include
swelling of the face, nose, mouth,
lips, tongue, larynx and/or the
extremities. This type of swelling
is called angioneurotic oedema
and it often occurs within the
first month of treatment or even
within hours of the initial dose.
Angiotensin receptor blockers
Angiotensin receptor blockers in-
hibit all the known hypertensive
effects mediated by AT1 receptors
and the effects that cause struc-
tural changes (Fig.). ARBs do not
inhibit the degradation of vasodi-
lating bradykinin, but they do ef-
fectively inhibit the tissue effects
of angiotensin II, which is proba-
bly formed by enzymes other
than ACE (e.g. chymase). Conse-
quently, ARBs are presumed to
cause an inhibition of the renin-
angiotensin system which is more
complete than that caused by
ACE inhibitors.
ARBs interrupt the renin se-
cretion inhibiting effect of an-
giotensin II thereby increasing
plasma renin activity and the an-
giotensin II concentration, espe-
cially at the start of treatment.
Consequently, the effect of an-
giotensin II, which circulates in
the blood and is formed in the
tissues, is solely targeted on un-
blocked AT2 receptors. The bio-
logical importance of this effect
remains unclear so far, but selec-
tive blockade of AT1 receptors is
a beneficial feature because the
AT2 receptor mediated effect pre-
venting hypertrophy appears to
be a pharmacologically important
property. An increase in the num-
ber of AT2 receptors in cardiac
cells may therefore possibly coun-
teract the AT1 receptor activation
(Fig.). The use of ABRs is estab-
lished in the treatment of hyper-
tension:  strokes, coronary artery
disease events, and mortality
from cardiovascular disease are
decreased by this therapy (4).
Renin inhibitors
The most significant progress in
research into the renin-an-
giotensin system in recent years
has been made in the study of
renin and drugs with an effect on
renin (1, 5–7). Renin secretion is
mainly regulated by renal perfu-
sion pressure, distal tubular sodi-
um concentration, sympathetic
nervous system activity (beta-1
receptor activation) and angio-
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tensin II, which directly inhibits
renin secretion by stimulating the
AT1 receptors in juxtaglomerular
cells (direct negative feedback)
(2). Renin inhibitors directly in-
hibit the activity of the first key
enzyme of the system, renin, re-
ducing plasma renin activity
(Fig.). The first one approved for
clinical use is aliskiren (1). The
peak plasma concentration of
aliskiren is achieved within 1–3
hours and its bioavailability is
about 2–3%. The average half-
life is about 40 hours. Aliskiren
is mainly eliminated unchanged
in the faeces and no interaction
with drugs metabolised via
CYP450 enzymes is expected (1).
Very fatty meals diminish the
peak concentration and AUC val-
ue of aliskiren, and the tablet
should therefore be taken with a
light meal and preferably at the
same time every day.
Aliskiren is indicated in the
treatment of hypertension either
alone or in combination with
other antihypertensives (1, 5–7).
The recommended dose is 150
mg/day, and the dose may be in-
creased to 300 mg once a day as
necessary. There is no need to
change the dose in renal or he-
patic insufficiency, nor in elderly
patients (1). Aliskiren reduces
blood pressure equally with oth-
er antihypertensives (1, 4–7), and
in combination with hydro-
chlorothiazide the effect was ad-
ditive as expected (8). Reports of
adverse reactions in patients re-
ceiving aliskiren and/or placebo
were almost equal in frequency,
with diarrhoea being the most
common adverse reaction. As
with the use of ACE inhibitors
and angiotensin receptor block-
ers, the concomitant use of
aliskiren with a potassium-spar-
ing diuretic, potassium supple-
ment or other serum potassium-
concentration increasing drug
may augment the increase in
serum potassium concentration.
There is no information at pre-
sent on the effects of aliskiren on
mortality and occurrence of car-
diovascular diseases. The effect
of aliskiren on type 2 diabetic
nephropathy is examined in the
ALTITUDE study, and the AT-
MOSPHERE study focuses on
the prevalence and mortality as-
sociated with cardiovascular dis-
eases (9). 
Dual inhibition of renin-
angiotensin system
Adequate reduction in blood
pressure is of key importance in
the treatment of hypertension,
and this often requires combina-
tion therapy. Combination thera-
py is used to produce additive or
synergistic effect, and two or
more drugs with different modes
of action are used concomitantly
(2). In combined use, homeostat-
ic factors limiting the antihyper-
tensive effect become less potent.
Diuretic therapy, for example, is
associated with activation of the
renin-angiotensin system as a re-
sult of loss of sodium; the activa-
tion can be effectively inhibited
by an ACE inhibitor, angiotensin
receptor blocker or a renin in-
hibitor. In theory, a combination
of two or more drugs with effects
on the renin-angiotensin system
also offers several benefits (1,
5–7, 10). By combining ACE in-
hibitor therapy and an angio-
tensin receptor blocker, all the ef-
fects of angiotensin II can be in-
hibited independently of how the
angiotensin II was formed. In the
combined treatment, any benefi-
cial bradykinin-mediated effects
of ACE inhibition may potentiate
the effects associated with the ac-
tivation of AT2 receptors by the
angiotensin receptor blockers
(Fig.).
Both ACE inhibitors and ATR
blockers interrupt the negative
feedback regulation of angio-
tensin II and thereby increase
renin secretion and plasma renin
activity (1). In hypertensive pa-
tients, high plasma renin activity
increases the risk of myocardial
infarction (11). The largest in-
crease has been found with the
combination of a renin inhibitor
and an angiotensin receptor
blocker. A great number of stud-
ies have focused on the increased
renin concentration during treat-
ment (12–14) because it has been
found that renin and prorenin
bound to the (pro)renin receptor
(15–18). (Pro)renin receptors are
found, for example, in the heart,
blood vessels and the kidneys,
where their activation probably
results in hypertrophy and fibro-
sis and may be of importance in
diabetes, for example, in view of
changes in blood vessels (19–20).  
Combined use of renin-
angiotensin system inhibitors
Renin-angiotensin system in-
hibitors are indicated in the treat-
ment of hypertension of all de-
grees of severity. Used as the sole
drug in the treatment of mild or
moderate essential hypertension,
the antihypertensive efficacy of
renin-angiotensin system in-
hibitors is similar to that of di-
uretics, beta-blockers or calcium
channel blockers, and an ade-
quate response to treatment is
achieved in over half of the pa-
tients treated. ACE inhibitors
and angiotensin receptor blockers
are useful in patients with type 2
diabetes or nephropathy, because
they reduce proteinuria and the
rate of deterioration of renal
function (4). Diabetes has oc-
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curred less frequently in the use
of ACE inhibitors and ARBs in
comparison with the use of med-
ication based on a diuretic, beta-
blocker or calcium channel block-
er (21). Adjunctive treatment
with a thiazide diuretic signifi-
cantly improves the efficacy of
the antihypertensive effect of all
renin-angiotensin system in-
hibitors. Renin-angiotensin sys-
tem inhibitors may also reduce
the risk of hypokalaemia caused
by thiazide diuretics (2). 
Combined treatment with a
calcium channel blocker and an
ACE inhibitor, angiotensin recep-
tor blocker or renin inhibitor is
also justified, because these com-
binations have a potent antihy-
pertensive effect. Ankle swelling
associated with calcium channel
blockers is significantly reduced
at the same time (2). According
to the ACCOMPLISH study, not
yet published, combining an ACE
inhibitor with a calcium channel
blocker in high risk patients is
more beneficial than combining
an ACE inhibitor with a diuretic
(Jamerson et al., ACC2008,
Chicago). The ACCOMPLISH
study is the first endpoint study
in which the drug initially used
was a comparison of a combina-
tion of two drugs with regard to
prevalence and mortality in the
treatment of hypertension (22).
Using a combination of an ACE
inhibitor (benazepril, 40 mg) and
a calcium channel blocker (am-
lodipine, 10 mg), prevalence and
mortality were reduced by more
than 20% compared with a com-
bination of an ACE inhibitor and
a diuretic (benazepril 40 mg + hy-
drochlorothiazide 25 mg).
A recent extensive study called
ONTARGET compared the effi-
cacy and tolerance of ramipril
and telmisartan and a combina-
tion of the two in high-risk pa-
tients (suffering from vascular
disease or diabetes) (23, 24). Dai-
ly doses of 10 mg ramipril were
given to 8,576 patients for a peri-
od of 4–5 years, 8,542 received
80 mg of temilsartan and 8,502
both drugs. The combination did
not demonstrate efficacy superior
to that of ramipril and was asso-
ciated with more frequent hy-
potension, syncope, hyper-
kalaemia and renal dysfunction.
The same study showed that an-
giotensin receptor blockers and
ACE inhibitors are equally effec-
tive inhibitors of cardiovascular
diseases, whereas angiotensin re-
ceptor blockers are better tolerat-
ed. The results are compatible
with the VALIANT study results,
according to which valsartan
(320 mg) and captopril (150 mg)
were equally effective in patients
who had suffered from myocar-
dial infarction (25). The VALIANT
study also showed that a maxi-
mum dose of an ACE inhibitor
(captopril) combined with an an-
giotensin receptor blocker (val-
sartan) resulted in a more potent
hypotensive effect and more se-
vere impairment of renal function
than did monotherapy, but the
combined therapy did not prove
to be more effective. Consequent-
ly, studies in high risk patients
and those who have suffered my-
ocardial infarction indicate that
maximum doses of an ACE in-
hibitor and angiotensin receptor
blocker do not reduce the num-
ber of endpoint events more than
monotherapy. It is also possible
that the adverse events associated
with combination therapies re-
duce the benefit.
In heart failure, on the other
hand, adding an angiotensin re-
ceptor blocker to the ACE in-
hibitor therapy was found to de-
crease the hospitalisations for
heart failure (26, 27) and cardio-
vascular mortality (26, the
CHARM-Added study); it should
be borne in mind, however, that
the dose of the ACE in these
studies was not a maximum dose
but was left to the discretion of
the doctor. Albuminuria when us-
ing the combination of an ACE
inhibitor and an angiotensin re-
ceptor blocker is also less severe
in comparison with monotherapy
using an ACE inhibitor or an an-
giotensin receptor blocker (28,
29).
Endpoint studies on combin-
ing a renin inhibitor with ACE
inhibitors or angiotensin receptor
blockers have not yet been pub-
lished. Nevertheless, when ali-
skiren is combined with ramipril
or valsartan, the effect on the
blood pressure is additive (30,
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31). Combination therapy using
maximum doses of aliskiren and
valsartan have been examined in
an extensive (> 1,700 patients) 
8-week study (31). The main
variable in the study was the re-
duction in the diastolic blood
pressure. The combination re-
duced the blood pressure signifi-
cantly more than monotherapy
(SBP/DBP, about 3.2 mm Hg).
The plasma renin activity was al-
so reduced as expected in the
combined therapy group (44%).
In hypertensive diabetics
aliskiren produced an additive
antihypertensive effect in adjunc-
tive therapy with ramipril (30).
When aliskiren was used con-
comitantly with ACE inhibitors
in diabetic or hypertensive pa-
tients, increased potassium con-
centration was more common.
Consequently, patients on other
renin-angiotensin system in-
hibitors and/or with impaired re-
nal function and/or diabetes have
a higher risk of hyperkalaemia
during aliskiren therapy.
Combined therapy may be su-
perior to monotherapy in pre-
venting target organ damage, e.g.
structural cardiac or vascular
changes (2). In the ALOFT study,
aliskiren was used as an adjunct
to conventional therapy (an ACE
inhibitor, angiotensin receptor
blocker, beta-blocker and/or al-
dosterone receptor blocker) in
hypertensive patients with heart
failure (32). Compared with the
placebo, aliskiren (150 mg, 12
weeks) reduced plasma NT-proB-
NP by 25% and urine aldos-
terone concentration by 21%.
The AVOID study examined the
combination of aliskiren with
losartan therapy and compared it
with a placebo in hypertensive
patients who suffered from type
2 diabetes and macroalbumin-
uria: aliskiren (300 mg, 24
weeks) reduced proteinuria by
18% (1). In a yet unpublished
(ALLAY, Solomon et al., ACC
2008, Chicago), the effects of
aliskiren (300 mg), losartan (100
mg) and a combination of these
on the blood pressure and left
ventricular hypertrophy were
compared (assessments carried
out by a magnetic study)(9). In
this study, the combination did
not reduce left ventricle hypertro-
phy more than monotherapy
with losartan, and the blood
pressure was not significantly
more reduced in the aliskiren/
losartan group.
Conclusion
The aims of antihypertensive
drug therapy are to produce an
effective reduction in blood pres-
sure and a reduction in the inci-
dence of cardiovascular diseases
and in mortality, while at the
same time causing as few adverse
reactions as possible. The blood
pressure lowering effects of ACE
inhibitors, angiotensin receptor
blockers and renin inhibitors are
equal, on average. Treatment
based on ACE inhibitors or an-
giotensin receptor blockers re-
duces coronary artery events,
strokes and cardiovascular mor-
tality, while studies have only re-
cently been initiated on renin in-
hibitors. Renin inhibitors are, in
fact, appropriate in antihyperten-
sive treatment in patients for
whom ACE inhibitors, for exam-
ple, are inappropriate due to the
adverse reactions associated with
them. Recent studies show that a
dual inhibition, a combination of
two drugs with effects on the
renin-angiotensin system, will
improve the antihypertensive ef-
fect, but further comparative
studies are needed focussing on
the antihypertensive effect of
these combinations and compar-
isons to the situations in which
two drugs which affect two to-
tally different blood pressure reg-
ulating systems are combined
(e.g. combining an angiotensin
receptor blocker with a diuretic
or a calcium channel blocker).
New endpoint studies are needed
because, in comparison with
monotherapy, the combination
of an ACE inhibitor and an an-
giotensin receptor blocker has
been associated with more inci-
dents of hypotension, hyper-
kalaemia and renal dysfunction.
Using the combination of two or
more renin-angiotensin system
inhibitors as antihypertensive
therapy might be appropriate in
specific cases, in treatment-resis-
tant hypertension, for example,
but this also requires a number
of further studies.
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Achieving the aims of generic substitution
Drug costs in recent decades rep-
resent the fastest growing cost
component in the Finnish health
care system. The mean annual in-
crease in drug costs in out-pa-
tient care was 11% from the year
1960 onwards until the begin-
ning of the 2000’s. The increase
has been caused both by in-
creased use, as pharmacotherapy
for new diseases is becoming
available, and by continuous
modifications in pharmacothera-
py, in that drugs recently intro-
duced on to the market are more
costly than those they replace.
Various measures have been
taken to scale down the increase
in the cost of drugs; one of them
is generic substitution, which has
been widely introduced in vari-
ous countries. In Finland the first
measures in this direction were
taken in 1993 with the introduc-
tion of voluntary generic substi-
tution. According to this model,
permission for any substitution
had to be obtained from the doc-
tor, who would need to be in
agreement. The system remained
in use until 1996, but it failed to
produce significant financial sav-
ings. Voluntary generic prescrip-
tions (using the generic name)
were introduced in 1996, but
they did not produce any notice-
able result either.
The present model of generic
substitution has been in use since
April 2003. In the government
proposal for a reform of the
Medicines Act, the aims of gener-
ic substitution were set as fol-
lows: promotion of cost-effective
pharmacotherapy; review of
sharing of responsibilities be-
tween the prescriber and the
pharmacist; improved patient
choice and improved efficiency of
competition in the drug market.
According to initial estimates, the
potential saving through generic
substitution, based on the cost
level of the year 2000, was 45
million euros, with an estimated
15 million euros of this sum be-
ing saved in the first year.
After a reform in the Medi-
cines Act, generic substitution
meant that pharmacies were im-
posed with the obligation to re-
place the drug prescribed by the
doctor with the most cost-effec-
tive product or a product which
would not differ greatly in its
cost range from the one original-
ly prescribed, unless opposed by
the prescriber or the purchaser of
the drug. This substitution con-
cerns the drugs that are included
in the list of substitutable drugs
by the National Agency for Med-
icines. The chief principle in
drawing up a list such as this is
to ensure the safety of the substi-
tution without any resultant
change in the effectiveness of the
drug. Substitution does not cover
groups of therapy where the
therapeutic regime is sensitive to
changes in the dose, nor does it
cover forms of drug that cannot
easily be proven to be equivalent.
The principles in drawing up the
list have been described in more
detail on the web pages of NAM.
The present list covers 46% of
all the drugs with market autho-
risation.
Excluded also, outside the
generic substitution by the re-
form of the Medicines Act in
2006, were drugs with a valid
methods patent in Finland and a
product patent in at least five
EEA countries. The government
bill circulated in May 2008, re-
garding the introduction of a ref-
erence price system, proposes
waiving the above restriction re-
garding patents. NAM supports
the proposal.
Total savings yielded in the
first year of generic substitution
were calculated at 88.3 million
euros (6% of drug costs). One
third of this was a direct result
of the substitution and two
thirds was due to the price com-
petition created by the substitu-
tion. The savings in 2007
amounted to 35.6 million euros,
half of which benefitted the cus-
tomers directly and the other
half was to the advantage of the
refund system.
In 2007 the Social Insurance
Institution refunded the cost of a
Erkki Palva
Professor, Head of Department
National Agency for Medicines
Generic substitution year 2007
Number of substitutable prescriptions: 
22 million
Volume of substitutions made: 11.9%
Volume of substitutions prescribed by 
doctors within the set price range: 74.7%
Client refused to accept substitution: 9.7%
Doctor refused to accept substitution: 0.2%
The drug not replaced with another one for 
some other reason: 3.5%
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total of 34.8 million prescriptions,
of which 22 million concerned
substitutable drugs (Table).
The development that has tak-
en place in the different areas of
therapy and drug groups is a per-
fect illustration of the importance
attached to generic substitution.
Fig. 1 shows the development of
sales and consumption of anti-
epilepsy drugs during 2002–2007.
Anti-epilepsy drugs are not cov-
ered by generic substitution, conse-
quently the development of this
group can be considered in some
ways as an example when compar-
ing general trends in development.
In the period under review the
costs have increased significantly
faster in comparison with the vol-
ume of consumption of drugs,
which is a result of the increased
share of new and relatively most
expensive drugs within this entire
group of drugs. The total drug
consumption and costs have
shown a similar trend in the past
few years.
Developments in the use and
sales of antidepressants as shown
in Fig. 2 illustrate what can be
achieved as described above in an
area of pharmacotherapy where
more recent and more expensive
drugs are also introduced: con-
sumption since 2002 has increased
by over 40%, whereas the costs
have diminished at the same time
by over 30%. Consequently, the
introduction of generic substitution
has allowed space for the use of
the more recent drugs, which are
excluded from the substitution,
without increasing the total costs.
The group of ACE inhibitors in
Fig. 3 is an example of a situation
where the effect of generic substi-
tution is especially great: despite
the increase of over 50% in con-
sumption, the cost has dropped by
80% at the same time.
The principles in drawing up a
list of substitutable medicinal
products include ensuring the safe
and successful outcome of generic
substitution without unexpected
changes in drug response or ad-
verse reactions. NAM has been
made aware of only isolated re-
ports of situations where the ad-
verse reaction caused by a drug, or
its lack of efficacy, has been sus-
pected of being associated with
substituting one drug with another.
Reviewing the entire period
over which generic substitution has
been in force, it can be maintained
that substitution is well established
as to the extent of its use and the
volume of savings made. Thus it
appears that the aims of saving
have been reasonably well
achieved by the system without
problems associated with the effi-
cacy or safety of the pharma-
cotherapy.
Fig. 1. Consumption and sales of anti-epilepsy drugs in 2002–2007.
Fig. 2. Consumption and sales of antidepressants in 2002–2007.
Fig. 3. Consumption and sales of ACE inhibitors in 2002–2007.
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Drug development mostly takes
place outside Finland. Complex
international networking is com-
mon in the field. This phenome-
non can also be seen in Finland as,
in 2007, 68% of the 250 notifica-
tions of clinical trials on medicinal
products filed with the National
Agency for Medicines (NAM)
concerned international multi-cen-
ter trials.
Performing trials on Finnish
population is important for scien-
tific reasons, and also for public
health and national economy.
Finns are often considered good
subjects because of their punctual
nature and positive attitude to-
wards research. Last year, 19% of
trials were performed on healthy
volunteers and 81% on patients.
Number of subjects in one trial
varied from one to tens of thou-
sands, with 25 subjects as median.
Last year, 18% of trials were
performed by academic re-
searchers, without outside financ-
ing or with financing by a non-
profit organization. The propor-
tion of commercial trials has
slightly increased during recent
years. Figure 1 shows clinical trial
notifications received by NAM
during 1998–2007, questions
raised during NAM assessment,
and NAM’s requests for addition-
al information due to incomplete
notifications. No significant
changes in the figures can be per-
ceived during the past ten years.
Clinical trials can be classified
into four phases (Figure 2). Of all
trials, phase III trials were the
most common (45%) in 2007.
There was no notable variation in
the number of phase I, II and IV
trials carried out in 2007 (17–19 %).
Figure 3 shows all investigational
medicinal products in 2007 sorted
according the Anatomical Thera-
peutic Chemical (ATC) code. Last
year, medication of nervous sys-
tem was the largest trial focus
(26% of all trials). Second largest
group was antineoplastic and im-
munomodulating agents (18%). 
Estimated duration of trials has
somewhat increased (Figure 4). In
2007, the planned duration was
on average nearly 2 years but in
the longest-spanning trials, it was
10–14 years. The proportion of
trials lasting less than one year has
slightly decreased. 
The complete 2007 statistics of
clinical trials in Finland is pub-
lished at NAM’s website in
Finnish (www.nam.fi).
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Fig 1. Number of notifications of clinical trials on medicinal products received by NAM, questions raised 
during NAM assessment and NAM’s requests for additional information due to incomplete notification.
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Phases of clinical trials
Phase I. Initial trials in hu-
mans on a new medicine.
These studies are usually con-
ducted on small populations of
healthy volunteers (excl. for
example cytotoxic drugs).
They are started with a small
single dose that is cautiously
raised. An attempt is made to
determine a drug’s safety and
tolerability of the dose range,
as well as toxicity, absorption,
distribution, metabolism and
excretion. Pharmacokinetic 
trials are usually considered
Phase I trials regardless of
when they are conducted 
during a medicine’s develop-
ment.
Phase II. A drug is tested for
safety and efficacy in a slightly
larger population of individu-
als who are affected with the
disease or condition for which
the drug was developed. Ob-
jectives may focus on dose-re-
sponse, frequency of dosing, or
numerous other characteristics
of safety, tolerability and effi-
cacy.
Phase III. The third rounds of
testing of a drug are multina-
tional trials conducted on large
populations of patients. Phase
III trials usually test the new
drug in comparison with the
standard therapy currently 
being used for the disease in
question. Most common 
adverse reactions and related
risk factors are studied.
Phase IV. Trials conducted 
after a medicinal product is
marketed. Different durations
of treatment, interactions, and
additional patient populations
or new age groups may be
evaluated. 
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Fig 4. Estimated duration of the clinical trials.
Fig 3. Investigational medicinal products sorted according to ATC code.
Fig 2. Clinical trials classified into four phases.
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